| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
To address the role of IP6K2 in amyotrophic lateral sclerosis (ALS), we investigated the expression level of IP6K2, employing G93A mutant human superoxide dismutase-1 over-expressing transgenic mice (Tg mice) as ALS. The specimens of spinal cords were obtained from Tg mice and week age-matched wild-type mice. We investigated the expression levels of IP6K2 on the genes and proteins in Tg and wild-type mice. The gene expression level of IP6K2 in Tg mice at postnatal 17 weeks around the onset of ALS symptoms was lower compared to that of wild-type mice, while at postnatal 12 weeks before the symptoms of ALS it was signifivantly higher compared to wild-type mice. In the immunohistochemistry against IP6K2, it was stained in the cytoplasm in Tg mice during each week-old. These findings suggest that IP6K2 might be activated in Tg mice before the onset of ALS. IP6K2 might be a pre-symptomatic biomarker for ALS.
|
